PVR and prostate cancer: Owing to the high correlation between CD155 and tumor metastasis, the efficacy of bispecific anti-CD3 and anti-CD155 (CD155Bi-Ab) antibodies, with ATC-specific cytotoxic activity, has been tested for the suppression of prostate cancer progression (53).